Home Cart Sign in  
Chemical Structure| 2567686-02-4 Chemical Structure| 2567686-02-4

Structure of Tulmimetostat
CAS No.: 2567686-02-4

Chemical Structure| 2567686-02-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, used in research on various solid tumors.

Synonyms: CPI-0209

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tulmimetostat

CAS No. :2567686-02-4
Formula : C28H36ClN3O5S
M.W : 562.12
SMILES Code : CC1=C2C(O[C@@]([C@@]3(CC[C@]([H])(CC3)N4CC(OC)C4)[H])(C)O2)=C(Cl)C=C1C(NCC5=C(SC)C=C(C)NC5=O)=O
Synonyms :
CPI-0209
MDL No. :N/A

Safety of Tulmimetostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Tulmimetostat

epigenetics

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04104776 Advanced Solid Tumor|Diffuse L... More >>arge B Cell Lymphoma|Lymphoma, T-Cell|Mesothelioma, Malignant|Prostatic Neoplasms, Castration-Resistant|Endometrial Cancer|Ovarian Clear Cell Carcinoma Less << PHASE1|PHASE2 RECRUITING 2026-03-01 Winship Cancer Institute of Em... More >>ory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States|South Texas Accelerated Research Therapeutics (Start) - Midwest Location, Grand Rapids, Michigan, 49546, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, 10461, United States|NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center, New York, New York, 10016, United States|Weill Medical College of Cornell University, New York, New York, 10065, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45219, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Fred Hutchinson Cancer, Seattle, Washington, 98109-1023, United States|Bergonie Institute, Bordeaux, 33000, France|Oscar Lambret Center, Lille, 59020, France|Leon Berard Center, Lyon, 69373, France|Hospital North, Nantes, 44093, France|Nantes University Hospital Center - Hotel Dieu Hospital (Satellite), Nantes, 44093, France|Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, 44093, France|Strasbourg Europe Institut of Cancerology, Strasbourg, 23025, France|Gustave Roussy, Villejuif, 94805, France|Irccs University Hospital of Bologna, Bologna, 40138, Italy|Gruppo Humanitas - Humanitas Research Hospital - Cancer Center, Milan, 20089, Italy|National Cancer Institute, IRCCS, Milan, 20133, Italy|European Institute of Oncology (IEO), IRCCS, Milan, 20141, Italy|University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Rome, 00168, Italy|Keimyung University - Dongsan Medical Center, Daegu, 42601, Korea, Republic of|National Cancer Center, Gyeonggi-do, 10408, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|University Teaching Centre, Early Clinical Trials Unit, Gdansk, 80-214, Poland|Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland|University Teaching Hospital in Poznan, Department of Gynecologic Oncology, Poznan, 60-569, Poland|Medical Center Pratia Poznan, Skorzewo,, Poland|Maria Sklodowska-Curie - National Research Institute of Oncology, Warsaw, Poland|University Clinical Hospital of Salamanca, Salamanca, Castilla Y Leon, 37007, Spain|University Hospital Complex of Santiago (CHUS), Santiago De Compostela, Galicia, Spain|University Hospital Vall d'Hebron, Barcelona, Spain|University Hospital of Girona Dr. Josep Trueta, Girona, Spain|University Clinic of Navarra - Madrid, Madrid, Spain|University Hospital 12 de Octubre, Madrid, Spain|University Hospital Quiron Madrid, Madrid, Spain|University Hospital Son Espases, Palma De Mallorca, Spain|University Clinic of Navarra - Pamplona, Pamplona, Spain|University Hospital Virgen del Rocio (HUVR), Seville, Spain|Valencia Oncology Institute (IVO), Valencia, Spain|Royal United Hospital, Bath, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Imperial College Healthcare NHS Trust, London, SW7 2AZ, United Kingdom|Royal Marsden Hospital - Sutton, Sutton, United Kingdom|Musgrove Park Hospital, Taunton, United Kingdom Less <<
NCT05467748 Non Small Cell Lung Cancer PHASE1|PHASE2 NOT_YET_RECRUITING 2029-02-01 VA Greater Los Angeles Healthc... More >>are System, West Los Angeles, CA, West Los Angeles, California, 90073-1003, United States Less <<
NCT05944562 Mycosis Fungoides|Sezary Syndr... More >>ome|Mycosis Fungoides/Sezary Syndrome Less << PHASE1 RECRUITING 2030-01-31 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.89mL

1.78mL

0.89mL

17.79mL

3.56mL

1.78mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories